Prelude Therapeutics (PRLD) executive compensation, 2026 proxy

Krishna Vaddi, Ph.D., Chief Executive Officer, was paid $1.3M in 2025, down 42% from $2.3M the year before.

Filed
April 29, 2026
Annual meeting
June 9, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.3M-42% vs prior year
CEO Target Bonus
50%Of base salary
CFO/CSO Target Bonus
40%Of base salary
CEO Option Awards
$412,744Granted in 2025
Total Shareholder Return
$67.92Value of initial fixed $100 investment
Net Loss
$(99.50)MFor fiscal 2025

How Ph.D. was paid

$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary46%Option awards31%Non-equity incentive23%All other compensation1%

Named executive officers

ExecutiveTotal
Krishna Vaddi, Ph.D.Chief Executive Officer$1,348,000
Peggy A. Scherle, Ph. D.Chief Scientific Officer$819,729
Bryant D. LimChief Legal Officer, Corporate Secretary, and Chief Financial Officer$847,397

What changed and why

  • $1.3MCEO total compensation decreased to $1,348,000 in fiscal 2025 from $2,327,471 in fiscal 2024.
  • $413KOption awards for the CEO totaled $412,744 in fiscal 2025, down from $1,446,379 in fiscal 2024.
  • $309KNon-equity incentive compensation of $309,465 was paid based on corporate performance and individual achievements.
  • Annual bonuses were approved in full following the achievement of corporate performance objectives.
  • $1.11Stock options were granted to named executive officers with an exercise price of $1.11.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.